RxDoctor Payments Data

Mila Ju, MD

Vascular Surgery · Allentown, PANPI 1629207352

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $23,850 of the $35,667 with a category attached, or 66.9%. Silk Road Medical, Inc. accounts for 94.4% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2022 at $18,842 and has fallen 98.8% since, to $227 in 2025. Among vascular surgery clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$35,667in general payments, 2019–2025

Across 95 payments — averaging $375.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Silk Road Medical, Inc.$34K
  • Medtronic$875
  • W. L. Gore & Associates, Inc.$651
  • Cook Medical LLC$189
  • Shockwave Medical, Inc$137
  • Boston Scientific$52
  • plus $99 from 4 others

What the payments were for

  • Consulting fees$23,85067%
  • Travel & lodging$7,98322%
  • Food & beverage$3,83511%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$35,667 in reported general payments places this provider in the 90th percentile of 236 vascular surgery providers in Pennsylvania.

See all vascular surgery providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$207,828
Medicare patients
744
Services billed
1,526

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban66$66,816
EliquisApixaban36$43,067
Cilostazol94$2,786
ClopidogrelClopidogrel Bisulfate186$2,677
Prednisone13$51

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$17$66,81666 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 236 vascular surgery providers in Pennsylvania.

Other vascular surgery in Allentown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →